3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
29
Carcinoma, Hepatocellular
18
Colorectal Neoplasms
17
Stomach Neoplasms
12
Esophageal Squamous Cell Carcinoma
10
Neoplasm Metastasis
9
Advanced Solid Tumor
9
Squamous Cell Carcinoma of Head and Neck
7
Lung Neoplasms
7
Head and Neck Neoplasms
7
Rectal Neoplasms
5
Small Cell Lung Carcinoma
4
Neoplasms
4
Nasopharyngeal Carcinoma
4
Melanoma
4
Esophageal Neoplasms
4
Solid Tumor
3
Lymphoma, Follicular
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Biliary Tract Neoplasms
3
Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Extranodal NK-T-Cell
2
Lymphoma
2
Hodgkin Disease
2
Interventions
toripalimab
2
zanidatamab
1
tislelizumab
1
disitamab vedotin
1
Probiotics
1
Gemcitabine
1
Cisplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Muscle Invasive Bladder Cancer (MIBC)
×
tislelizumab
×
1 year
×
Clear all
NCT07296705
2025-12-22
HARBOR
Fujian Medical University Union Hospital
Phase 2
Recruiting
25 enrolled